Matthew C. Abernethy

CFO

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2025	Neurocrine Biosciences Inc (NBIX)	Chief Financial Officer	$725,913	$526,000	$2,499,918	$2,500,036	—	$60,045	$6,311,912
2024	Neurocrine Biosciences Inc (NBIX)	Chief Financial Officer	$684,824	$452,840	$2,599,987	$2,799,904	—	$57,646	$6,595,201
2023	Neurocrine Biosciences Inc (NBIX)	Chief Financial Officer	$646,061	$355,335	$1,812,563	$3,187,536	—	$56,387	$6,057,882
2022	Neurocrine Biosciences Inc (NBIX)	Chief Financial Officer	$618,240	$373,262	$1,570,128	$2,310,061	—	$52,632	$4,924,323
2021	Neurocrine Biosciences Inc (NBIX)	Chief Financial Officer	$588,800	$264,960	$2,375,068	$2,625,019	—	$53,003	$5,906,850
2020	Neurocrine Biosciences Inc (NBIX)	Chief Financial Officer	$545,200	$190,820	$2,500,266	$2,999,869	—	$45,021	$6,281,176
2019	Neurocrine Biosciences Inc (NBIX)	Chief Financial Officer	$495,600	$284,970	$1,250,035	$3,750,345	—	$42,170	$5,823,120
2018	Neurocrine Biosciences Inc (NBIX)	Chief Financial Officer	$420,000	$199,500	$1,996,506	—	—	$69,741	$2,685,747
2017	Neurocrine Biosciences Inc (NBIX)	Chief Financial Officer	$38,231	$20,071	$920,000	$2,416,800	—	$394,190	$3,789,292